Abterra Biosciences (United States)

Optimizing efficacy to safety ratio of glucocorticoids in rheumatoid arthritis models by leveraging PPARα agonism

ABSTRACT Objectives Glucocorticoids remain essential therapies for several immune- and inflammatory diseases such as rheumatoid arthritis (RA) but are notorious for their (metabolic) side effects. Given the anti-inflammatory and metabolically favorable actions of peroxisome-proli...

Stoichiometry-Dependent Specificity in Biotin Enrichment: A Benchmarking Framework for Proximity-Labeling Proteomics

ABSTRACT Proximity labeling methods (including, BioID, TurboID, ultraID), along with surface proteomics and microdomain mapping, enable proteome-wide identification of spatially proximal proteins via MS-based analysis. These workflows require specific enrichment of biotinylated p...

Protein LanguageModel Decoys for Target Decoy Competitionin Proteomics: Quality Assessment and Benchmarks

Abstract Large-scale proteomics relies heavily on target–decoy competition for false discovery rate estimation in peptide identification, and the performance of this strategy depends strongly on the design of the decoy database. Classical generators such as reversal and shuffling...

OvercomingElectrochemiluminescence Immunoassay (ECLIA)Limitations: Conformation-Independent Quantitation of a TherapeuticAntibody by LC–MS/MS

Abstract Monoclonal antibody therapies have transformed cancer treatment by enabling targeted intervention even in advanced disease stages. However, reliable monitoring of circulating therapeutic antibody levels is critical to ensuring efficacy and patient safety. This study inve...